Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 70.1 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Fc,Avitag (Cat. No. RO1-H82F4) is more than 95% and the molecular weight of this protein is around 160-195 kDa verified by SEC-MALS.
Immobilized Anti-ROR1 Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Fc,Avitag (Cat. No. RO1-H82F4) with a linear range of 0.2-6 ng/mL (QC tested).
2e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 10 μg/mL of Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Fc,Avitag (Cat. No. RO1-H82F4) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).
Price(USD) : $360.00
Price(USD) : $1565.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Zilovertamab vedotin | VLS-101; MK-2140 | Phase 3 Clinical | Oncternal Therapeutics Inc, University Of California San Diego | Neuroblastoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Sarcoma, Ewing; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Richter's Syndrome; Lymphoma, Follicular; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Hematologic Neoplasms | Details |
Zilovertamab | UC-961 | Phase 2 Clinical | University Of California San Diego, Oncternal Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Immunoproliferative Disorders; Lymphatic Diseases; Immune System Diseases; Prostatic Neoplasms, Castration-Resistant; Lymphoma, Mantle-Cell; Breast Neoplasms; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
EMB-07 | EMB-07 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms | Details |
PB-004 | PB004; PBA-0405; PB004 PureBIKE; PB-004 | Phase 1 Clinical | Pure Biologics SA | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Sarcoma | Details |
PRGN-3007 | PRGN-3007 | Phase 1 Clinical | Precigen Inc | Hematologic Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
HDM-2005 | HDM2005; HDM-2005 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Lymphoma | Details |
NM32-2668 | NM-32-2668 | Phase 1 Clinical | Numab Therapeutics Ag | Leiomyosarcoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Liposarcoma; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Melanoma | Details |
LYL-797 | LYL-797 | Phase 1 Clinical | Lyell Immunopharma Inc | Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
LCB-71 | CS-5001; LCB-71; ABL-202; ROR1-pPBD | Phase 1 Clinical | Legochem Biosciences Inc, Abl Bio Inc | Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma | Details |
SIM-201 | SIM-201; SIM-0201 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.